Simplify Logo

Full-Time

Associate Director/Principal Scientist

Immunology Discovery Research

Confirmed live in the last 24 hours

Generation Bio

Generation Bio

51-200 employees

Developing genetic medicines with non-viral delivery

Hardware
Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in immunology or related field with minimum of 6 years relevant experience required
  • Experience across multiple fields of immunology, such as deep knowledge of diverse cell types and disease areas required
  • Track record of contributing to a cross-functional project team and enabling achievement of milestones as a leader and collaborative team player
  • Deep understanding of flow cytometry and immunophenotyping with complex flow panels
  • Previous experience designing pharmacology studies required
  • Curious, detail oriented, eager to tackle hard problems, and ability to communicate complex issues effectively
Responsibilities
  • Conceptualize experimental path to evaluate novel target biology and design PoC in vitro experiments
  • Contribute to the strategic thinking of novel target concepts
  • Design and execute in vivo pharmacology studies in WT and disease models
  • Analyze and report data, synthesizing key results and crafting strategic path forward
  • CRO management in collaboration with preclinical operations group
  • Project leadership, responsible for balancing resources and executing on deliverables, with the ability to influence, design, and scope out new project initiatives in a matrixed team
  • Mentor direct reports and other scientists within the group

Generation Bio

Company Stage

IPO

Total Funding

$536.4M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-11%

1 year growth

-23%

2 year growth

-20%
Simplify Jobs

Simplify's Take

What believers are saying

  • The development of iqDNA and ctLNP platforms positions Generation Bio at the forefront of genetic medicine innovation, potentially leading to breakthrough treatments for rare and prevalent diseases.
  • Strategic reorganization and cost-saving measures extend the company's cash runway into the second half of 2027, providing financial stability and continued investment in R&D.
  • High-profile presentations at conferences and collaborations with industry leaders like Moderna enhance the company's visibility and credibility in the biotech sector.

What critics are saying

  • The 40% workforce reduction as part of the strategic reorganization could impact employee morale and productivity.
  • Dependence on successful integration and advancement of iqDNA and ctLNP platforms carries inherent risks if the technologies do not perform as expected in clinical settings.

What makes Generation Bio unique

  • Generation Bio's focus on non-viral genetic medicines using proprietary immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms sets it apart from traditional gene therapy companies.
  • Their scalable capsid-free manufacturing process, utilizing rapid enzymatic synthesis (RES), offers a unique advantage in producing genetic medicines efficiently.
  • The strategic collaboration with Moderna highlights Generation Bio's innovative approach and industry recognition.